- Cytolon and T-Cell Europe agree on cooperation
- Cytolon initiates global development of DIT - Distributed-Inventory-TechnologyTM
- Cytolon joins Personalized Medicine Coalition
- Cytolon successful with second financing round
- Cytolon gains Patent for CordMatch® in Australia
- Cytolon and DKMS Cord Blood Bank announce collaboration for CordMatch’s Beta-Testing Phase
- Timm Jessen Joins Cytolon’s Supervisory Board
- Cytolon Partners with iSoft for New Life Science Research Tool
- Michaela Servas joins Cytolon´s Supervisory Board
- Cytolon Co-Founder Prof. Dr. Joachim Dudenhausen receives Order of Merit
- CordMatch® goes live
- Cytolon Partners with CSC to Develop CordMatch®
- Cytolon Closes Its First Round of Financing
- Wolfgang Jünger Joins Cytolon's Supervisory Board
- Katherina Reiche, MdB, Steps Down From Cytolon's Supervisory Board to Become a Member of the Federal Government of Germany
- Cytolon Receives the "MOST PROMISING COMPANY LAUNCHED IN 2009 AWARD"
- Cytolon Announces Cooperative Agreement with ARCWAY
- Start-up Financing Begins
- The Launching of Cytolon AG
Start-up Financing Begins
Dr. Jürgen Schumacher, co-founder of Qiagen, is a Leading Investor
Berlin, October 31st 2008 – Cytolon AG announced today the closing of their start-up financing, with the amount and conditions of the investment not disclosed. A lead investor is Dr. Jürgen Schumacher, an internationally recognized German entrepreneur and co-founder of Qiagen AG, German's biggest biotechnology company with 3500 employees. Dr. Schumacher is also co-founder of NewLab Bioquality AG which he sold to Charles River International Inc. in 2008. Besides bringing a versatile involvement in industry associations and organizations, Mr. Schumacher invests in start-up and growth phase technology companies with exceptional prospects and outstanding management. Thomas Klein, Founder and Chief Executive Officer of Cytolon AG, states "we are extremely pleased to count on Dr. Schumacher, a wonderful entrepreneur who is undoubtedly one of the top Business Angels in Germany in the Biotechnological field". Mr. Klein goes on to say "Dr. Schumacher is not only an investor but is also a partner and member of Cytolon's Supervisory Board." Dr. Schumacher is convinced that his investment in Cytolon will pay off handsomely. Dr. Schumacher states "Thomas Klein is one of Germany's most successful Biotech entrepreneurs with a proven track record and Cytolon is one of the first movers in personalized health services. This enterprise will be a leading company in the near future". About Cytolon AG: Cytolon AG is a private Company based in Berlin, Germany that has developed a proprietary, patent-pending, global, internet-based cord blood brokering platform termed CordMatch®. Cytolon's mission is to be the world's first trusted source for getting the correct, best-matched cord blood unit (CBU) to the patient that needs it in a timely manner. For more information, please visit the company's Web site at www.cytolon.com.
Contact:
Nina Hofle - PR Manager
Cytolon AG
Am Karlsbad 15
10785 Berlin - Germany
phone: +49 (0) 30 2639 288-0
fax: +49 (0) 30 2639 288-20
e-mail: info@cytolon.com
web: www.cytolon.com